Crispr Therapeutics shares tumble after significant earnings miss
Jefferies upgraded Syensqo SA (SYENS:BB) stock rating from hold to buy on Monday, raising its price target to EUR80.00 from EUR70.00.
The upgrade came as part of Jefferies’ mid-year outlook, despite the firm’s fiscal year 2025 EBITDA forecasts sitting approximately 5% below consensus estimates.
Jefferies projects medium-term earnings growth of 8% for Syensqo, compared to 5% for its peers, highlighting the specialty chemicals company’s stronger growth potential.
The research firm noted Syensqo has maintained net pricing in materials for the past seven quarters, which it considers a key positive indicator for the company.
This pricing power "suggests an underlying portfolio quality greater than peers," according to Jefferies’ analysis of the Brussels-based chemical company’s business fundamentals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.